NCT00926120已完成2 期
A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener "PureLo" on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- To assess the efficacy of administering Mogroside sweetener "PureLo" at a dosage level of 5 g every 6 hours over 15 in subjects with chronic hepatitis C (CHC) with respect to the following: hepatitis C viral load; serum ALT levels.
研究概览
简要总结
The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
详细描述
The primary objectives of the study are to assess the safety and efficacy of administering Mogroside Sweetener "PureLo" to genotype 1 subjects at a dose level of 5 grams every 6 hours for 14 days on hepatitis C viral load and serum ALT levels. Percentage change in HCV load over the first 48 hours and daily for 14 days and change in serum ALT levels over the two week period of study, will be calculated for each patient. The number of subjects who show a decline in viral load of at least 50% will then be calculated, as will the number of subjects who decrease their serum ALT levels by at least 50%. All efficacy and safety analysis will be conducted at the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Serologic evidence of HVC infection by an anti-HCV antibody test.
- •Serum HCV RNA quantifiable > 20,000 copies/mL at screening period and demonstrate abnormal ALT > 40 for 6 months.
- •No clinical suspicion or radiological evidence of hepatocellular carcinoma and a serum AFP < 50 ng/mL.
- •Negative urine pregnancy test for women of childbearing potential documented within the 24-hour period prior to the first dose for test drug.
排除标准
- •Interferon with or without RBV therapy at any previous time or any other systemic antiviral therapy or investigational drug > 3 months prior to the first dose of study drug.
- •Subjects who are expected to need systemic antiviral therapy at any time during the study are also excluded.
- •Positive test at screening for anti-HAV 1gM Ab, HbsAg, anti-HBc IgM Ab, or anti-HIV Ab.
- •Documented serum concentrations of ceruloplasmin or Alpha 1-antitrypsin consistent with an increased risk of metabolic liver disease.
- •History or other evidence of a medical condition associated with chronic liver disease (e.g., haemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures).
- •Women with ongoing pregnancy or breast feeding
- •Neutrophil count < 1000 cells/mm3, Hgb <11 g/dL in women or 12 g/dL in men, or platelet count < 80,000 cells/mm
- •Serum creatinine level > 2 times the upper limit of normal at screening.
- •Evidence of alcohol and/or drug abuse within one year of entry.
- •History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquillizer at therapeutic doses for major depression or psychosis, respectively, for at least 4 months at any previous time or any history of the following:
- •a suicidal attempt
- •hospitalization for psychiatric disease, OR
- •a period of disability due to a psychiatric disease.
- •History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematous, autoimmune hemolytic anemia, scleroderma, severe psoriasis, sarcoidosis, etc.).
- •History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease including ascites or hepatic encephalopathy.
- •History or other evidence of chronic pulmonary disease associated with functional limitation.
- •History of severe cardiac disease.
- •History of a severe seizure disorder or current anticonvulsant use.
- •Evidence of an active or suspected cancer or a past history of malignancy other than skin cancer.
- •History of having received any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤ 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- •History of major organ transplantation with an existing functional graft.
- •History of thyroid disease poorly controlled on prescribed medications.
- •History or other evidence of severe retinopathy.
- •Inability or unwillingness to provide informed consent or abide by the requirements of the study.
- •History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
结局指标
主要结局
To assess the efficacy of administering Mogroside sweetener "PureLo" at a dosage level of 5 g every 6 hours over 15 in subjects with chronic hepatitis C (CHC) with respect to the following: hepatitis C viral load; serum ALT levels.
时间窗: 30 days
次要结局
未报告次要终点
研究者
Stephen A Harrison
Principal Investigator
Brooke Army Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerOvarian CancerNCT00400348CASI Pharmaceuticals, Inc.18
撤回
2 期
A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking NutralinDiabetesNCT01275027Avera McKennan Hospital & University Health Center
终止
2 期
A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral NeuropathyDiabetic Peripheral NeuropathyNCT01087203Pfizer73
已完成
2 期
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)Alpha 1-Antitrypsin DeficiencyNCT03946449Arrowhead Pharmaceuticals16
已完成
2 期
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19Severe COVID-19NCT04733833Vascular Biogenics Ltd. operating as VBL Therapeutics5